Dose-dependent effects of fingolimod on behavioral, molecular, and Stereological outcomes in a rat model of intracerebroventricular streptozotocin-induced Alzheimer’s disease-like cognitive dysfunction
Aug 2026· 3 Biotech· Vol 16· 0 citations· 96 references
Medicine
TL;DR
Fingolimod exerted dose-dependent, domain-specific effects, with lower doses improving functional outcomes and the intermediate dose providing greater preservation of hippocampal structure, suggesting beneficial effects within the doses examined.
Alzheimer's disease (AD) is characterized by progressive cognitive decline, amyloid-β (Aβ) accumulation, oxidative stress, and neuroinflammation. Increasing evidence links metabolic dysfunction to AD, suggesting that antidiabetic drugs such as metformin may exert neuroprotective effects. This study investigated the eff...
Farzane Shanehbandpour-Tabari, Ravieh Golchoobian, F. Pourabdolhossein· European Journal of Pharmaco...· 0 citations
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive dysfunction and impaired synaptic plasticity. This study evaluated whether chronic L-carnitine (LC) attenuates amyloid-beta 1-42 (Aβ₁-₄₂)-induced spatial learning and memory deficits following intracerebroventricular (ICV) A...
It is suggested that FMNT attenuates PTZ-kindling-associated seizure severity and cognitive deficits, potentially through antioxidant effects and suppression of P2 X 7/IL-1β/glutamate-associated inflammatory signalling.
Harsh Yadav, B. Thawkar, Nisarg S. Sawant· Neurochemical Research· 0 citations
Background Alzheimer’s disease (AD) is a gradual neurodegenerative disorder presenting with cognitive and non-cognitive impairment. Currently approved therapies alleviate symptoms but do not modify disease progression and may be associated with adverse effects. Objective This study aimed to compare the effect of niloti...
Anurag Kumar, Nasreen Fatima, Pramod Kumar et al.· Annals of Neurosciences· 0 citations
Empagliflozin confers robust behavioral, antioxidant, anti-inflammatory, and neuroprotective effects during methamphetamine withdrawal, and this animal study support empagliflozin as a potential treatment for neuropsychiatric dysfunction associated with METH withdrawal.
H. Ghavimi, M. Ebrahimi, Maede Hasanzadeh et al.· Iranian journal of pharmaceu...· 0 citations
Alzheimer’s disease (AD) is an increasingly prevalent neurodegenerative disorder worldwide, with women showing a higher risk of developing the disease. The decline in steroid hormones after menopause may contribute to the increased susceptibility of women to neurodegenerative conditions. In parallel, cannabis-derived c...
M. Mirshekar, Farzaneh Nadi, Hamed Fanaei et al.· IBRO Neuroscience Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.